Definitive Analysis
Financial Statements
Periods / Units
Fundamentals
Valuations
Miscellaneous
Analysis Mode
Full Access
See Pricing Start Trial
Multiples Valuation: Royalty Pharma plc

Royalty Pharma plc (RPRX)

Industry: Biotechnology Model: Peers Multiples Valuation

Valuation Snapshot

Winsorized Fair Value
Range (Low - High) $9.40 — $44.56
Selected (Average) $21.71
Upside to Live -45.10%
Full Range Fair Value
Range (Low - High) $11.53 — $85.56
Selected (Average) $30.91
Upside to Live -21.84%
Live Price $39.55

Industry Peers Data

TickerRankNameRev TTM (M) Trailing P/EForward P/ETrailing EV/EBITDAForward EV/EBITDATrailing EV/EBITForward EV/EBIT
ALNY 17 Alnylam Pharmaceut 3,210 1,375.87 1,375.87 328.19 328.19 41.59 231.29
UTHR 18 United Therapeutic 3,128 14.44 11.83 9.97 8.20 10.95 9.47
FTRE 19 Fortrea Holdings I 2,760 - - - - - -
1801.HK 20 Innovent Biologics 2,680 - - - - 38.95 -
068270.KS 21 Celltrion, Inc. 2,639 51.54 47.91 25.29 22.23 33.27 42.53
1530.HK 22 3SBio Inc. 2,483 13.02 8.67 10.22 6.77 10.34 6.91
600866.SS 23 Star Lake Bioscien 2,355 9.84 6.30 6.41 4.01 18.81 6.04
RPRX 24 Royalty Pharma plc 2,350 20.36 25.21 14.49 16.46 13.43 16.66
BLU 25 BELLUS Health Inc. 2,302 - - - - - -
EXEL 26 Exelixis, Inc. 2,288 15.87 11.77 12.24 9.01 11.16 9.60
MRNA 27 Moderna, Inc. 2,221 - - - - - -
300759.SZ 28 Pharmaron Beijing 1,914 41.67 38.42 25.08 21.58 33.11 34.32
2096.HK 29 Simcere Pharmaceut 1,909 - - 8.86 8.86 8.53 25.70
BIOCON.BO 30 Biocon Limited 1,820 89.92 95.18 16.38 14.01 38.58 14.63
ALKS 31 Alkermes plc 1,786 14.62 14.62 10.11 6.09 12.37 12.29
PTCT 32 PTC Therapeutics, 1,779 6.41 6.41 4.99 4.99 377.43 5.87

Implied Valuation Analysis

Line Item Trailing P/EForward P/ETrailing EV/EBITDAForward EV/EBITDATrailing EV/EBITForward EV/EBIT
Winsorized Median Multiple14.6211.8310.118.2015.599.60
Full Range Median Multiple15.2513.2210.228.8625.9612.29
Industry Multiple163.32161.7041.6139.4552.9236.24
Market Implied Multiple22.3527.6715.4517.5514.3217.76
Company (RPRX) Multiple20.3625.2114.4916.4613.4316.66
(*) Net Income / EBITDA / Revenue7656181,5831,3941,7091,378
Winsorized Enterprise ValueN/AN/A16,01311,43426,63313,227
Full Range Median Enterprise ValueN/AN/A16,18512,35444,35516,935
(-) Net Debt7,3717,3717,3717,3717,3717,371
Winsorized Equity Value11,1817,3078,6434,06419,2635,856
Full Range Median Equity Value11,6628,1698,8144,98436,9859,564
(/) Shares Outstanding432432432432432432
Winsorized Fair Value$25.87$16.90$19.99$9.40$44.56$13.55
Full Range Median Fair Value$26.98$18.90$20.39$11.53$85.56$22.12
Current Price$39.55$39.55$39.55$39.55$39.55$39.55
Upside / Downside-34.60%-57.26%-49.45%-76.23%12.67%-65.75%
Safety Margin30.0%30.0%30.0%30.0%30.0%30.0%
Buy Price$18.11$11.83$13.99$6.58$31.19$9.48
Buy / Don't BuyDon’t BuyDon’t BuyDon’t BuyDon’t BuyDon’t BuyDon’t Buy